43 results
8-K
EX-10.1
RNLX
Renalytix Plc
12 Jun 24
Departure of Directors or Certain Officers
5:00pm
not relate to the business efforts or research and development efforts in which, during the term of this Agreement, the Company actually is engaged
424B5
RNLX
Renalytix Plc
15 May 24
Prospectus supplement for primary offering
10:09am
, expanded research and development activities and costs associated with operating a public company.
Our expected use of the net proceeds from … factors, including the results of our research and development efforts, the timing of regulatory submissions, our ability to obtain additional financing
8-K
EX-99.1
RNLX
Renalytix Plc
15 May 24
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2024
7:00am
the year ago period.
Within operating expenses, research and development expenses were $2.2 million for the three months ended March 31, 2024 … ,
(in thousands, except share data)
Revenue
Cost of revenue
Gross profit (loss)
Operating expenses:
Research and development
General and administrative
424B5
RNLX
Renalytix Plc
9 Apr 24
Prospectus supplement for primary offering
4:31pm
, including conducting verification studies, commercialization efforts, expanded research and development activities and costs associated with operating … from this offering. The amounts and timing of our expenditures will depend upon numerous factors, including the results of our research and development
8-K
EX-99.1
3elh1dw
15 Feb 24
Renalytix Reports Financial Results for Second Quarter of Fiscal Year 2024
7:00am
10-Q
smx2 rdrvlb07
14 Nov 23
Quarterly report
12:00am
8-K
EX-99.1
iz1i6sd 4xma
14 Nov 23
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2024
12:00am
8-K
EX-99.1
3uy9 ih0p6tc
28 Sep 23
Renalytix Reports Full Year Fiscal 2023 Results
7:31am
POS AM
6dkl37ib0 jl3bze
28 Sep 23
Prospectus update (post-effective amendment)
6:55am
POS AM
a08laml55dylg441u jh
28 Sep 23
Prospectus update (post-effective amendment)
6:54am
10-K
izeqlwy3xc
28 Sep 23
Annual report
6:18am
6-K
vmhe 8xlq7j4j9dg
9 Jun 23
Current report (foreign)
7:01am
424B3
0we51yosoku
10 May 23
Prospectus supplement
4:14pm
F-3
j2bhmv9t1jb0m6xbxgqi
2 May 23
Shelf registration (foreign)
4:40pm
6-K
do3lp8v84kc 5mpidcb1
30 Mar 23
Current report (foreign)
7:01am
6-K
gwmv95hkxuv ls
30 Nov 22
Current report (foreign)
7:31am
6-K
EX-99.1
ykc37 6x4c0
22 Nov 22
Annual Report and For the Year Ended 30 June 2022
5:09pm
6-K
EX-99.3
mqoyr4e9m 4bnhg
22 Nov 22
Annual Report and For the Year Ended 30 June 2022
5:09pm